Abstract
Somatostatin analogues and mTOR inhibitors have been used as medical therapy in lung carcinoids with variable results. No data are available on dopamine agonists as treatment for lung carcinoids. The main aim of the current study was to evaluate the effect of the combined treatment of somatostatin analogue octreotide and the dopamine agonist cabergoline with mTOR inhibitors in an in vitro model of typical lung carcinoids: the NCI-H727 cell line. In NCI-H727 cell line, reverse transcriptase-quantitative polymerase chain reaction and immunofluorescence were assessed to characterize the expression of the somatostatin receptor 2 and 5, dopamine receptor 2 and mTOR pathway components. Fifteen typical lung carcinoids tissue samples have been used for somatostatin receptor 2, dopamine receptor 2, and the main mTOR pathway component p70S6K expression and localization by immunohistochemistry. Cell viability, fluorescence-activated cell sorting analysis and western blot have been assessed to test the pharmacological effects of octreotide, cabergoline and mTOR inhibitors, and to evaluate the activation of specific cell signaling pathways in NCI-H727 cell line. NCI-H727 cell line expressed somatostatin receptor 2, somatostatin receptor 5 and dopamine receptor 2 and all mTOR pathway components at messenger and protein levels. Somatostatin receptor 2, dopamine receptor 2, and p70S6K (non phosphorylated and phosphorylated) proteins were expressed in most typical lung carcinoids tissue samples. Octreotide and cabergoline did not reduce cell viability as single agents but, when combined with mTOR inhibitors, they potentiate mTOR inhibitors effect after long-term exposure, reducing Akt and ERK phosphorylation, mTOR escape mechanisms, and increasing the expression DNA-damage-inducible transcript 4, an mTOR suppressor. In conclusion, the single use of octreotide and cabergoline is not sufficient to block cell viability but the combined approach of these agents with mTOR inhibitors might reduce the mTOR inhibitors-induced escape mechanisms and/or activate the endogenous mTOR suppressor, potentiating the effect of the mTOR inhibitors in an in vitro model of typical lung carcinoids.
Similar content being viewed by others
References
W.D. Travis. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart—the Concept of Pulmonary Neuroendocrine Tumours. (IARC, Lyon), (2004) 19–20
W.D. Travis, The 2015 WHO classification of lung tumors. Pathologe. 35(Suppl 2), 188 (2014). doi:10.1007/s00292-014-1974-3
E.M. Bertino, P.D. Confer, J.E. Colonna, P. Ross, G.A. Otterson, Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer 115(19), 4434–4441 (2009). doi:10.1002/cncr.24498
M.E. Caplin, E. Baudin, P. Ferolla, P. Filosso, M. Garcia-Yuste, E. Lim, K. Oberg, G. Pelosi, A. Perren, R.E. Rossi, W.D. Travis, participants, E.c.c., Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. (2015). doi: 10.1093/annonc/mdv041
G.A. Kaltsas, G.M. Besser, A.B. Grossman, The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev. 25(3), 458–511 (2004). doi:10.1210/er.2003-0014
D. Horsch, K.W. Schmid, M. Anlauf, K. Darwiche, T. Denecke, R.P. Baum, C. Spitzweg, C. Grohe, N. Presselt, C. Stremmel, D.F. Heigener, M. Serke, T. Kegel, M. Pavel, C.F. Waller, K.M. Deppermann, R. Arnold, R.M. Huber, M.M. Weber, H. Hoffmann, Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol. Res. Treat. 37(5), 266–276 (2014). doi:10.1159/000362430
P.L. Filosso, P. Ferolla, F. Guerrera, E. Ruffini, W.D. Travis, G. Rossi, P.O. Lausi, A. Oliaro; European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering, C., Multidisciplinary management of advanced lung neuroendocrine tumors. J. Thorac. Dis. 7(Suppl 2), S163–171 (2015). doi:10.3978/j.issn.2072-1439.2015.04.20
S.W. Lamberts, E.P. Krenning, J.C. Reubi, The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12(4), 450–482 (1991). doi:10.1210/edrv-12-4-450
R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S.W. Lamberts, L.J. Hofland, Novel insights in dopamine receptor physiology. Eur J. Endocrinol. 156(Suppl 1), S13–21 (2007). doi:10.1530/eje.1.02353
R. Baldelli, A. Barnabei, L. Rizza, A.M. Isidori, F. Rota, P. Di Giacinto, A. Paoloni, F. Torino, S.M. Corsello, A. Lenzi, M. Appetecchia, Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front. Endocrinol. (Lausanne) 5, 7 (2014). doi:10.3389/fendo.2014.00007
E.T. Janson, K. Oberg, Neuroendocrine tumors—somatostatin receptor expression and somatostatin analog treatment. Cancer. Chemother. Biol. Response. Modif. 21, 535–546 (2003)
D. Kaemmerer, E. Specht, J. Sanger, R.M. Wirtz, M. Sayeg, S. Schulz, A. Lupp, Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J. Clin. Endocrinol. Metab. 100(3), 831–840 (2015). doi:10.1210/jc.2014-2699
L. Righi, M. Volante, V. Tavaglione, A. Bille, L. Daniele, T. Angusti, F. Inzani, G. Pelosi, G. Rindi, M. Papotti, Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann. Oncol. 21(3), 548–555 (2010). doi:10.1093/annonc/mdp334
M.C. Zatelli, M. Minoia, C. Martini, F. Tagliati, M.R. Ambrosio, M. Schiavon, M. Buratto, F. Calabrese, E. Gentilin, G. Cavallesco, L. Berdondini, F. Rea, E.C. degli Uberti, Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer. 17(3), 719–729 (2010). doi:10.1677/ERC-10-0097
M. Kidd, A.V. Schally, R. Pfragner, M.V. Malfertheiner, I.M. Modlin, Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer. 112(6), 1404–1414 (2008). doi:10.1002/cncr.23303
E. Diakatou, K.I. Alexandraki, A.V. Tsolakis, G. Kontogeorgos, E. Chatzellis, A. Leonti, G.A. Kaltsas, Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin. Endocrinol. (Oxf) 83(3), 420–428 (2015). doi:10.1111/cen.12775
G. Kanakis, L. Grimelius, A. Spathis, R. Tringidou, G.Z. Rassidakis, K. Oberg, G. Kaltsas, A.V. Tsolakis, Expression of somatostatin receptors 1-5 and dopamine receptor 2 in lung carcinoids: implications for a therapeutic role. Neuroendocrinology 101(3), 211–222 (2015). doi:10.1159/000381061
E. Diakatou, G. Kaltsas, M. Tzivras, G. Kanakis, E. Papaliodi, G. Kontogeorgos, Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. Endocr. Pathol. 22(1), 24–30 (2011). doi:10.1007/s12022-011-9149-8
K. Tsuta, I.I. Wistuba, C.A. Moran, Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. Pathol. Res. Pract. 208(8), 470–474 (2012). doi:10.1016/j.prp.2012.05.014
A. Colao, A. Faggiano, R. Pivonello, Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog. Brain. Res. 182, 281–294 (2010). doi:10.1016/S0079-6123(10)82012-6
A. Rinke, H.H. Muller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.F. Pape, M. Blaker, J. Harder, C. Arnold, T. Gress, R. Arnold, P.S. Group, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656–4663 (2009). doi:10.1200/JCO.2009.22.8510
M.E. Caplin, M. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedlackova, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, S. Martinez, J. Blumberg, P. Ruszniewski, C. Investigators, Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371(3), 224–233 (2014). doi:10.1056/NEJMoa1316158
K. Oberg, P. Hellman, P. Ferolla, M. Papotti, E.G.W. Group, Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii120–123 (2012). doi:10.1093/annonc/mds267
K. Lemmer, G. Ahnert-Hilger, M. Hopfner, S. Hoegerle, S. Faiss, P. Grabowski, M. Jockers-Scherubl, E.O. Riecken, M. Zeitz, H. Scherubl, Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life. Sci. 71(6), 667–678 (2002)
M. Kidd, I. Drozdov, R. Joseph, R. Pfragner, M. Culler, I. Modlin, Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113(4), 690–700 (2008). doi:10.1002/cncr.23700
R. Srirajaskanthan, J. Watkins, L. Marelli, K. Khan, M.E. Caplin, Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89(3), 308–314 (2009). doi:10.1159/000179899
E. Grossrubatscher, S. Veronese, P.D. Ciaramella, R. Pugliese, M. Boniardi, L. De Carlis, M. Torre, M. Ravini, M. Gambacorta, P. Loli, High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer. Biol. Ther. 7(12), 1970–1978 (2008)
R. Pivonello, D. Ferone, W.W. de Herder, A. Faggiano, L. Bodei, R.R. de Krijger, G. Lombardi, A. Colao, S.W. Lamberts, L.J. Hofland, Dopamine receptor expression and function in corticotroph ectopic tumors. J. Clin. Endocrinol. Metab. 92(1), 65–69 (2007). doi:10.1210/jc.2006-0728
R.S. Auriemma, L.F. Grasso, R. Pivonello, A. Colao, The safety of treatments for prolactinomas. Expert. Opin. Drug. Saf. 15(4), 503–512 (2016). doi:10.1517/14740338.2016.1151493
L.F. Grasso, R. Pivonello, A. Colao, Investigational therapies for acromegaly. Expert. Opin. Investig. Drugs. 22(8), 955–963 (2013). doi:10.1517/13543784.2013.805201
F. Mouton, F. Faivre-Defrance, C. Cortet-Rudelli, R. Assaker, G. Soto-Ares, S. Defoort-Dhellemmes, S. Blond, J.L. Wemeau, M.C. Vantyghem, TSH-secreting adenoma improved with cabergoline. Ann. Endocrinol. (Paris) 69(3), 244–248 (2008). doi:10.1016/j.ando.2008.02.001
R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of cushing’s disease. Endocr. Rev. 36(4), 385–486 (2015). doi:10.1210/er.2013-1048
L. Righi, M. Volante, I. Rapa, V. Tavaglione, F. Inzani, G. Pelosi, M. Papotti, Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr. Relat. Cancer. 17(4), 977–987 (2010). doi:10.1677/ERC-10-0157
G.I. Manfredi, A. Dicitore, G. Gaudenzi, M. Caraglia, L. Persani, G. Vitale, PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine 48(2), 363–370 (2015). doi:10.1007/s12020-014-0380-1
J. Chan, M. Kulke, Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr. Treat. Options. Oncol. 15(3), 365–379 (2014). doi:10.1007/s11864-014-0294-4
S. Grozinsky-Glasberg, M. Pavel, Inhibition of mTOR in carcinoid tumors. Target. Oncol. 7(3), 189–195 (2012). doi:10.1007/s11523-012-0225-x
F. Meric-Bernstam, A.M. Gonzalez-Angulo, Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27(13), 2278–2287 (2009). doi:10.1200/JCO.2008.20.0766
M.P. DeYoung, P. Horak, A. Sofer, D. Sgroi, L.W. Ellisen, Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22(2), 239–251 (2008). doi:10.1101/gad.1617608
J.C. Yao, N. Fazio, S. Singh, R. Buzzoni, C. Carnaghi, E. Wolin, J. Tomasek, M. Raderer, H. Lahner, M. Voi, L.B. Pacaud, N. Rouyrre, C. Sachs, J.W. Valle, G. Delle Fave, E. Van Cutsem, M. Tesselaar, Y. Shimada, D.Y. Oh, J. Strosberg, M.H. Kulke, M.E. Pavel; Rad001 in Advanced Neuroendocrine Tumours, F.T.S.G., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022), 968–977 (2016). doi:10.1016/S0140-6736(15)00817-X
B. Svejda, M. Kidd, A. Kazberouk, B. Lawrence, R. Pfragner, I.M. Modlin, Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117(18), 4141–4154 (2011). doi:10.1002/cncr.26011
E. Bajetta, L. Catena, N. Fazio, S. Pusceddu, P. Biondani, G. Blanco, S. Ricci, M. Aieta, F. Pucci, M. Valente, N. Bianco, C.M. Mauri, F. Spada, Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer 120(16), 2457–2463 (2014). doi:10.1002/cncr.28726
M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. Horsch, R.E. Winkler, J. Klimovsky, D. Lebwohl, V. Jehl, E.M. Wolin, K. Oberg, E. Van Cutsem, J.C. Yao, R.-S. Group, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808), 2005–2012 (2011). doi:10.1016/S0140-6736(11)61742-X
N. Fazio, D. Granberg, A. Grossman, S. Saletan, J. Klimovsky, A. Panneerselvam, E.M. Wolin, Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 143(4), 955–962 (2013). doi:10.1378/chest.12-1108
T. Aoki, F. Motoi, N. Sakata, T. Naitoh, Y. Katayose, S. Egawa, J. Miyazaki, M. Unno, Somatostatin analog inhibits the growth of insulinoma cells by p27-mediated G1 cell cycle arrest. Pancreas 43(5), 720–729 (2014). doi:10.1097/MPA.0000000000000128
S. Grozinsky-Glasberg, G. Franchi, M. Teng, C.A. Leontiou, A. Ribeiro de Oliveira Jr., P. Dalino, N. Salahuddin, M. Korbonits, A.B. Grossman, Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 87(3), 168–181 (2008). doi:10.1159/000111501
S.C. Li, C. Martijn, T. Cui, A. Essaghir, R.M. Luque, J.B. Demoulin, J.P. Castano, K. Oberg, V. Giandomenico, The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One 7(10), e48411 (2012). doi:10.1371/journal.pone.0048411
A. Moreno, A. Akcakanat, M.F. Munsell, A. Soni, J.C. Yao, F. Meric-Bernstam, Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer. 15(1), 257–266 (2008). doi:10.1677/ERC-07-0202
C. Pivonello, M. Negri, M.C. De Martino, M. Napolitano, C. de Angelis, D.P. Provvisiero, G. Cuomo, R.S. Auriemma, C. Simeoli, F. Izzo, A. Colao, L.J. Hofland, R. Pivonello, The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget (2016). doi: 10.18632/oncotarget.6836
R. Rasmussen, in Quantification on the LightCycler, ed. by S. Meuer, C. Wittwer, K.-i. Nakagawara , Rapid cycle real time PCR: methods and applications (Springer, Heidelberg, 2001), pp. 21–34
T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6), 1101–1108 (2008)
M.W. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic. Acids. Res. 29(9), e45 (2001)
M.C. De Martino, R.A. Feelders, W.W. de Herder, P.M. van Koetsveld, F. Dogan, J.A. Janssen, A.M. Waaijers, C. Pivonello, S.W. Lamberts, A. Colao, R.R. de Krijger, R. Pivonello, L.J. Hofland, Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocr. Relat. Cancer. 21(4), 601–613 (2014). doi:ERC-13-0112 [pii] 10.1530/ERC-13-0112
A. Naalsund, H. Rostad, E.H. Strom, M.B. Lund, T.E. Strand, Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study. Eur. J. Cardiothorac. Surg. 39(4), 565–569 (2011). doi:10.1016/j.ejcts.2010.08.036
J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008). doi:10.1200/JCO.2007.15.4377
E. Bajetta, L. Catena, G. Procopio, S. De Dosso, E. Bichisao, L. Ferrari, A. Martinetti, M. Platania, E. Verzoni, B. Formisano, R. Bajetta, Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer. Chemother. Pharmacol. 59(5), 637–642 (2007). doi:10.1007/s00280-006-0306-6
D. Granberg, B. Eriksson, E. Wilander, P. Grimfjard, M.L. Fjallskog, K. Oberg, B. Skogseid, Experience in treatment of metastatic pulmonary carcinoid tumors. Ann. Oncol. 12(10), 1383–1391 (2001)
L.J. Wirth, M.R. Carter, P.A. Janne, B.E. Johnson, Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung. Cancer. 44(2), 213–220 (2004). doi:10.1016/j.lungcan.2003.11.016
L. Bodei, M. Cremonesi, M. Kidd, C.M. Grana, S. Severi, I.M. Modlin, G. Paganelli, Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac. Surg. Clin. 24(3), 333–349 (2014). doi:10.1016/j.thorsurg.2014.04.005
R. Srirajaskanthan, C. Toumpanakis, A. Karpathakis, L. Marelli, A.M. Quigley, M. Dusmet, T. Meyer, M.E. Caplin, Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung. Cancer. 65(1), 68–73 (2009). doi:10.1016/j.lungcan.2008.10.025
P.L. Filosso, E. Ruffini, A. Oliaro, E. Papalia, G. Donati, O. Rena, Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur. J. Cardiothorac. Surg. 21(5), 913–917 (2002)
R. Pivonello, D. Ferone, S.W. Lamberts, A. Colao, Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N. Engl. J. Med. 352(23), 2457–2458 (2005). doi:10.1056/NEJM200506093522322
O.D. Bruno, K. Danilowicz, M. Manavela, D. Mana, M.A. Rossi, Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review. Endocr. Pract. 16(5), 829–834 (2010). doi:10.4158/EP09286.CR
T. Gagliano, M. Bellio, E. Gentilin, D. Mole, F. Tagliati, M. Schiavon, N.G. Cavallesco, L.G. Andriolo, M.R. Ambrosio, F. Rea, E. Degli Uberti, M.C. Zatelli, mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr. Relat. Cancer. 20(4), 463–475 (2013). doi:10.1530/ERC-13-0042
K.E. O’Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer. Res. 66(3), 1500–1508 (2006). doi:10.1158/0008-5472.CAN-05-2925
Funding
This study has not received any specific support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A.C. has been Principal Investigator of Research studies for Novartis, Ipsen, and Pfizer; received research grants from Novartis, Ipsen, Pfizer, Ferring, Lilly, Novo Nordisk, HRA Pharma, and Italfarmaco; has been an occasional consultant for Novartis, Ipsen, Pfizer, and Italfarmaco; and has received fees and honoraria for presentations from Novartis and Ipsen. R.P. has been Principal Investigator of Research Studies for Novartis; received research grants from Novartis, Pfizer, HRA Pharma, and Viropharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Viropharma, Ferring, and Italfarmaco; and has received fees and honoraria for presentations from Novartis.
Additional information
Claudia Pivonello and Panagoula Rousaki have contributed equally to this work
Rights and permissions
About this article
Cite this article
Pivonello, C., Rousaki, P., Negri, M. et al. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine 56, 603–620 (2017). https://doi.org/10.1007/s12020-016-1079-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1079-2